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Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-
vascular Endothelial Growth Factor versus Laser Photocoagulation for 
Retinopathy of Prematurity
Hyun Goo Kang1, Tae Young Kim1, Jinu Han1, Sueng-Han Han2
1Department of Ophthalmology, Institute of Vision Research, Gangnam Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea 
2Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 
Purpose: To compare long-term refractive outcomes associated with intravitreal anti-vascular endothelial growth 
factor (VEGF) versus laser photocoagulation treatment for retinopathy of prematurity (ROP).
Methods: A total of 52 eyes from 27 ROP patients treated at two tertiary referral-based hospitals from August 
2006 to December 2013 were reviewed. The primary outcome was refractive error measured at the age of 4 
years, accounting for within-patient inter-eye correlation. Secondary outcomes included the recurrence rate and 
treatment complications.
Results: The mean age at refraction was 4.7 ± 0.3 years in the laser group (n = 30) and 4.4 ± 0.3 years in the an-
ti-VEGF group (n = 22). No significant differences were noted in gestational age, birthweight, post-menstrual age 
at treatment, or ROP stage/zone distribution between groups. Mean spherical equivalent was also not significant-
ly different (-1.0 diopters in the laser group and -0.3 diopters in the injection group, p = 0.603). Clustered regres-
sion analysis revealed that only gestational age was significantly correlated with mean spherical equivalent (p < 
0.001; 95% confidence interval, -0.007 to -0.002). Recurrence was noted in four eyes (13.3%) in the laser group, 
but this difference was not significant (p = 0.128). There were no major systemic complications reported in either 
group.
Conclusions: Treatment type, whether laser or anti-VEGF injection, does not appear to influence long-term re-
fractive outcomes in ROP. Concern regarding refractive outcomes should not be the most important factor when 
selecting ROP treatment modality.
Key Words: Intravitreal injections, Laser therapy, Refractive errors, Retinopathy of prematurity, Vascular endotheli-
al growth factor A 
Retinopathy of prematurity (ROP) is a proliferative reti-
nal vascular disease that develops in premature infants 
[1,2]. The incidence of childhood blindness due to ROP 
ranges from 3% to 10% worldwide [3-6]. Normal retinal 
vascular growth and development are disrupted by fetal 
environmental changes. Physiological hyperoxia causes 
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vascular endothelial growth factor (VEGF)-mediated ces-
sation of retinal vascular development [2,7]. The release of 
VEGF also causes vitreoretinal neovascularization, which 
leads to retinal traction, detachment, and hemorrhage, with 
profound loss of visual function [8-10].
Early detection and appropriately-timed intervention are 
critical to treatment and long-term outcomes of this dis-
ease [11-13]. Current treatment strategies include early 
treatment with laser photocoagulation based on the 2004 
Early Treatment for Retinopathy of Prematurity study [14], 
or with intravitreal anti-VEGF injections, based on 
groundbreaking studies such as the 2011 Bevacizumab 
Eliminates the Angiogenic Threat ROP study [12], either 
alone or in combination [15,16]. Although there are many 
benefits to anti-VEGF therapy, several studies have found 
temporary systemic suppression of VEGF and other 
growth factors after intravitreal injection in neonatal in-
fants [17,18], triggering concern regarding potential neuro-
logical or developmental delays [19].
One particularly concerning long-term consequence of 
ROP treatment is the elevated rate of myopia and high my-
opia in these infants, especially with the already high prev-
alence in Korean and Japanese populations [20]. Although 
several studies have noted greater prevalence and severity 
of myopia in laser-treated eyes over anti-VEGF, there are 
striking limitations due to the wide range of ages at refrac-
tion and variation in treatment zone, which were not al-
ways taken into account [21,22].
Therefore, in this study we examined the long-term re-
fractive outcomes of infants treated for ROP by collecting 
a large number of cases and adjusting for age at the time of 
refraction in analysis. We also noted the rate of recurrence 
and the incidence of systemic complications.
Materials and Methods
This retrospective case study was performed at two ter-
tiary referral-based hospitals, Severance Hospital and 
Gangnam Severance Hospital, which are affiliated with 
Yonsei University College of Medicine. Consecutive in-
fants diagnosed with ROP and treated from August 2006 
to December 2013 were included, and their medical charts 
were reviewed. This study was conducted with institution-
al review board approval from Gangnam Severance Hospi-
tal (3-2018-0050) and adhered to the tenets of the Declara-
tion of Helsinki. Informed consent was obtained from the 
parents or guardians of all subjects.
Infants were screened for ROP if they were born at ges-
tational age <32 weeks and their birthweight was <1,500 g; 
more mature and larger infants were examined if the clini-
cal course was complex and/or unstable, as determined by 
the primary neonatologist. All ophthalmic examinations 
were performed by qualified ophthalmologists using the 
revised guidelines of the 2005 International Committee for 
the Classification of ROP to determine the stage and zone 
[23]. The indications for treatment were infants who met 
the criteria for type 1 ROP used in the Early Treatment for 
Retinopathy of Prematurity study [14], although earlier 
treatment was performed at the primary ophthalmologists’ 
discretion in cases involving signs of clinical pre-plus dis-
ease, which was defined as abnormal vascular changes in-
sufficient for the diagnosis of plus disease.
For laser photocoagulation, infants were treated under 
general anesthesia using an indirect diode laser system 
with a handheld aspheric lens using scleral depression. For 
anti-VEGF injection, either bevacizumab (0.625 mg/0.025 
mL; off-label Avastin, Genentech, San Francisco, CA, 
USA) or ranibizumab (0.2 mg/0.02 mL; Lucentis, Novartis, 
Basel, Switzerland) [18,24] was injected into the diseased 
eye aseptically at the pars plana, 0.5 to 1 mm posterior to 
the limbus, using a sterile 30-gauge needle. The patients 
were re-examined the next day and then every week to 
monitor disease progression. Dilated fundus examinations 
were performed with indentation indirect ophthalmoscopy 
at every visit to confirm disease regression and vascular-
ization up to the ora serrata.
All infants underwent regular follow-up visits and eye 
examination including initial cycloplegic retinoscopy or 
subsequent manifest refraction by certified ophthalmolo-
gists. If hyperopia was noted at the initial cycloplegic re-
fraction, subsequent examinations were done with cyclo-
plegic refraction. The spherical and cylinder power, as well 
as the spherical equivalent (SE) are all noted in diopters 
(D). Patients who underwent vitrectomy or scleral buckling 
due to retinal detachment (five eyes from three patients), 
who underwent both laser and anti-VEGF injection (five 
eyes from three patients), or who lacked refraction data (54 
eyes from 28 patients) were excluded. 
The patients were grouped according to the type of 
treatment received: intravitreal anti-VEGF or laser photo-
coagulation. The main outcome was long-term refractive 
274
Korean J Ophthalmol Vol.33, No.3, 2019
error measured at the age of 4 years. Secondary outcomes 
included recurrence rate and treatment complications.
Statistical analyses were performed using Stata ver. 13.1 
(Stata Corp., College Station, TX, USA). Values are ex-
pressed as mean ± standard deviation, with ranges given 
when appropriate. Chi-square test (Fisher exact test) and 
analysis of variance were used to compare the two treat-
ment groups. A generalized estimating equation was used 
to compare refractive error between groups. Generalized 
estimating equation models that accounted for age at the 
time of refractive error measurement and within-patient 
inter-eye correlations were used to compare SE between 
the two treatment groups. Clustered regression analysis 
was used with each individual representing one cluster to 
consider similar characteristics between the right and left 
eyes in a single child and was performed to assess the im-
pact of various factors on refractive outcomes. A p-value 
less than 0.05 was considered statistically significant.
Results
Refractions were available for 27 of 55 (49.1%) eligible 
patients. The baseline characteristics of each treatment 
group are summarized in Table 1. A total of 30 eyes (15 
subjects) were treated with laser and 22 eyes (12 subjects) 
with anti-VEGF. In the anti-VEGF group, 20 (90.9%) eyes 
were treated with bevacizumab and 2 (9.1%) with ranibi-
zumab. There were no significant differences between the 
two groups in sex ratio, gestational age, birthweight, 
post-menstrual age at treatment, and ROP stage/zone distri-
bution. The mean age at refraction was 4.7 ± 0.3 years for 
the laser group and 4.4 ± 0.3 years for the anti-VEGF group.
Refractive outcomes
Refractive error grouped according to the treatment 
zone is summarized in Table 2. No significance was noted 
in mean SE between treatment groups (-1.0 D in the laser 
group vs. -0.3 D in the anti-VEGF group, p = 0.603). Simi-
larly, no differences were found in mean spherical or cyl-
inder power.
The distribution of refractive outcomes, categorized as 
Table 1. Baseline patient characteristics 
Laser-treated Anti-VEGF–treated p-value
Primary initial treatment 30 (57.7) 22 (42.3)
Sex
Male 16 (53.3) 14 (63.6) 0.573
Female 14 (46.7) 8 (36.4) 0.573
Birthweight (g) 961.0 ± 286.5 983.2 ± 265.6 0.775
GA at birth (wk) 34.0 ± 2.9 27.4 ± 2.0 0.188
PMA at initial treatment (wk) 52.2 ± 3.4 39.5 ± 2.3 0.081
Initial ROP classification
Stage 3 30 (100) 22 (100) -
Zone
1 2 (6.7) 4 (18.2) 0.382
2 28 (93.3) 18 (81.8) 0.382
Presence of plus sign 27 (90.0) 14 (63.6) 0.037*
APROP 0 (0) 1 (4.5) 0.423
Tunica vasculosis lentis 2 (6.7) 4 (18.2) 0.382
Values are presented as number (%) or mean ± standard deviation.
VEGF = vascular endothelial growth factor; GA = gestational age; PMA = post-menstrual age; ROP = retinopathy of prematurity; AP-
ROP = aggressive posterior retinopathy of prematurity.
*p < 0.05.
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high hyperopia to very high myopia, can be seen in Fig. 1. 
These refractive categories were chosen based on previous 
studies [25,26]. There were no significant differences in 
the distribution between the two groups. When combining 
all myopia (≥-1 D), there were 11 eyes (36.7%) in the laser 
group and 8 (36.4%) in the injection group, which was not 
a significant difference (p = 0.607). Additionally, no dif-
ferences in the prevalence of myopia between the treat-
ment groups were found when grouped according to the 
treatment zones.
Clustered regression analysis revealed that only gesta-
tional age showed significant correlation with the mean SE 
(p < 0.001; 95% confidence interval, -0.007 to -0.002). Oth-
er factors such as the treatment type, ROP treatment zone, 
and birthweight were not significant factors.
Complications and recurrences
Systemic complications and recurrences requiring addi-
tional treatment can be found in Table 3. No systemic 
complications were reported in either treatment group. The 
rate of recurrences requiring additional treatment was 
13.3% (n = 4) for the laser group and 0% (n = 0) for the an-
ti-VEGF group (p = 0.128). Fully vascularized retinas to 
the ora serrata were noted in 22 (100%) eyes in the an-
ti-VEGF group.
Discussion
Despite a recent trend in treating ROP primarily with 
intravitreal anti-VEGF injections, due in part to potential 
systemic complications, a large proportion of infants are 
Table 2. Refractive error after laser indirect ophthalmoscopy therapy or intravitreal anti-VEGF injection for treating retinopathy 
of prematurity
Laser-treated 
(n = 30 eyes)
Anti-VEGF–treated 
(n = 22) p-value
Mean spherical power
Zone 1 (2 vs. 4) -0.75 ± 2.83 -0.88 ± 2.49 -
Zone 2 (28 vs. 18) -0.29 ± 3.50 0.57 ± 5.33 0.496
Mean cylinder power
Zone 1 (2 vs. 4) -3.88 ± 0.88 -0.69 ± 0.38 -
Zone 2 (28 vs. 18) -1.00 ± 3.52 -0.32 ± 5.51 0.294
Mean spherical equivalence
Zone 1 (2 vs. 4) -2.69 ± 3.27 -1.22 ± 2.63 -
Zone 2 (28 vs. 18) -1.00 ± 3.52 -0.32 ± 5.51 0.603
Mean age at last refraction (yr) 4.7 ± 0.3 4.4 ± 0.3 0.007*
Zone 1 (2 vs. 4) 4.9 ± 0.0 4.1 ± 0.0 <0.001*
Zone 2 (28 vs. 18) 4.7 ± 0.3 4.5 ± 0.3 0.113
VEGF = vascular endothelial growth factor.
*p < 0.05.
Fig. 1. Distribution of the refractive outcome in spherical equiv-
alences after treatment for retinopathy of prematurity. Refractive 
error was divided into six categories: very high myopia (≥-8 di-
opters [D]), high myopia (<-8 to -5 D), low myopia (<-5 to -1 D), 
emmetropia (<-1 to +1 D), low hyperopia (>+1 to +4 D), and high 
hyperopia (>+4 D). No significant difference was noted between 
treatment groups in children at the age of 4 years. VEGF = vas-
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still treated via laser therapy [27,28]. Owing to several 
studies reporting an association between myopia and laser 
treatment, concern regarding long-term refractive out-
comes may inf luence primary ophthalmologists’ recom-
mendations regarding treatment method [25,29]. In our 
study, we found that in children aged 4 years, the type of 
treatment (laser or injection) did not appear to influence 
long-term refractive outcomes of ROP.
Conflicting results have been reported in a few studies 
regarding the long-term refractive outcomes of ROP treat-
ment [30], with major limitations acknowledged due to the 
wide range of ages and low number of cases involved. A 
literature review by Aghdam et al. [20] in 2016 found that 
mean final refractive error in 9 studies ranged from -4.4 to 
-10.1 D in laser-treated eyes and +0.4 to -3.7 D in injec-
tion-treated eyes, only one study reporting that outcomes 
were similar. However, age at the time of refraction ranged 
from 7 to 76 months with potential observer bias and small 
sample sizes, which made drawing definitive conclusions 
difficult. In our study of children aged 4 years, we noted no 
statistically significant differences in spherical/cylinder 
power and calculated SE between laser- or anti-VEGF-treat-
ed eyes.
When we compared the effects of treatment zones in the 
development of myopia, we noted that there was an overall 
trend toward more severe myopia in eyes treated closer to 
the posterior pole (zone 1 vs. zone 2), which varies from a 
previous report where no difference in myopia severity 
was noted between zone 1 and posterior zone 2 ROP [25]. 
Unfortunately, the number of cases treated in Zone 1 in 
our study was too small to draw meaningful statistical 
conclusions. Additionally, we noted no statistically signifi-
cant differences when myopia severity was compared be-
tween laser and anti-VEGF in each treatment zone. Thus, 
our results suggest that the greater proportion of myopia 
noted in children treated for ROP is an outcome intrinsic 
to the disease [31], and not necessarily influenced by type 
of treatment.
In terms of safety, we found no reports of systemic com-
plications such as neurodevelopmental delay or death in ei-
ther treatment group. The recurrence rate was 0% for la-
ser- and 13.3% for anti-VEGF-treated eyes, which is low 
compared to previously published studies with rates rang-
ing from 13% to 35.4% [32-34]. In cases with zone 2 or 3 
ROP, laser therapy appears to be a viable treatment option 
due to its lower rate of recurrence, especially in cases in 
which timely follow-up is difficult or there may be low 
compliance to additional therapies. However, the an-
ti-VEGF group was observed to have fully vascularized 
retinas up to the ora serrata in 100% of eyes on the most 
recent follow-up.
This study has several limitations. First, it was a retro-
spective study with a variable follow-up period and with-
out appropriate controls, such as those for treatment indi-
cations that might call for earlier treatment for type 1 ROP. 
Second, our study population was limited to Asian patients 
in a tertiary university hospital setting. Third, not all sys-
temic complications may have been properly observed or 
reported to us from the neonatologists. Finally, we did not 
routinely perform f luorescein angiography to document 
fully vascularized retinas in these children; however, a ret-
ina specialist performed thorough fundus examination at 
each follow-up outpatient visit. The strengths of this study 
include statistical comparison of long-term refractive out-
comes of similarly-aged children treated at two affiliated 
institutions using the same treatment protocols.
Table 3. Systemic complications and recurrence after laser therapy or intravitreal anti-VEGF injection for retinopathy of prema-
turity
Laser-treated 
(n = 30 eyes)
Injection-treated 
(n = 22) p-value
Complications
Systemic complications (death, etc.) 0 (0) 0 (0) -
Strabismus operation 10 (33.3) 12 (54.5) 0.161
Recurrence requiring additional treatment
Additional laser 4 (13.3) 0 (0) 0.128
Additional anti-VEGF injection 0 (0) 0 (0) -
Values are presented as number (%).
VEGF = vascular endothelial growth factor.
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In conclusion, our study demonstrated that long-term re-
fractive outcomes in infants treated for ROP did not vary 
between laser and anti-VEGF injection treatment groups. 
Concern regarding refractive outcome should not be the 
most important factor when selecting treatment modality. 
Considering the low rate of recurrence and established 
safety, conventional laser therapy remains a viable prima-
ry therapeutic option in select cases.
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